Polycyclic aromatic hydrocarbon-DNA adducts and survival among women with breast cancer.
Polycyclic aromatic hydrocarbon-DNA adducts and survival among women with breast cancer.
复制标题
DOI：
10.1016/j.envres.2008.11.005
复制
发表时间：
2009-04
影响因子：
8.3
通讯作者：
Gammon, Marilie D.
中科院分区：
文献类型：
--
作者：
Sagiv, Sharon K.;Gaudet, Mia M.;Eng, Sybil M.;Abrahamson, Page E.;Shantakumar, Sumitra;Teitelbaum, Susan L.;Bell, Paula;Thomas, Joyce A.;Neugut, Alfred I.;Santella, Regina M.;Gammon, Marilie D.
在动物研究中，多环芳烃（PAH）是乳腺癌致癌物，一些流行病学研究表明，PAH-DNA加合物水平升高与乳腺癌发病率之间存在联系。PAH-DNA加合物与乳腺癌患者生存率之间的相关性此前尚未报道。我们对1996年至1997年间新诊断为浸润性乳腺癌的妇女进行了生存分析，这些妇女参加了长岛乳腺癌研究项目。从诊断后不久和治疗前的血液样本中分离DNA，并使用ELISA测定PAH-DNA加合物。在722例PAH-DNA加合物测量病例中，截至2002年12月31日，国家死亡指数（NDI）报告了97例（13.4%）全因死亡和54例（7.5%）乳腺癌死亡。使用考克斯比例风险模型并控制诊断时的年龄，我们没有发现全因死亡率（风险比（HR）= 0.88; 95%置信区间（CI）：0.57-1.37）或乳腺癌死亡率（HR = 1.20; 95% CI：0.63-2.28）与不可检测的加合物相比，与可检测的PAH-DNA加合物水平密切相关;此外，未观察到剂量-反应相关性。在一个有治疗数据的亚组（n=520）中，加合物与接受放射治疗的死亡率高出两倍以上相关，但加合物的死亡率在激素治疗使用者中降低。这项大规模人群研究的结果并没有为可检测到的PAH-DNA加合物与乳腺癌女性生存率之间的关联提供强有力的支持，可能接受放射治疗的女性除外。
Polycyclic aromatic hydrocarbons (PAH) are mammary carcinogens in animal studies, and a few epidemiologic studies have suggested a link between elevated levels of PAH-DNA adducts and breast cancer incidence. An association between PAH-DNA adducts and survival among breast cancer cases has not been previously reported. We conducted a survival analysis among women with newly diagnosed invasive breast cancer between 1996 and 1997, enrolled in the Long Island Breast Cancer Study Project. DNA was isolated from blood samples that were obtained from cases shortly after diagnosis and before treatment, and assayed for PAH-DNA adducts using an ELISA. Among the 722 cases with PAH-DNA adduct measurements, 97 deaths (13.4%) from all causes and 54 deaths (7.5%) due to breast cancer were reported to the National Death Index (NDI) by December 31, 2002. Using Cox proportional hazards models and controlling for age at diagnosis, we did not find evidence that all-cause mortality (hazard ratio (HR) = 0.88; 95% confidence interval (CI): 0.57–1.37), or breast cancer mortality (HR = 1.20; 95% CI: 0.63–2.28) was strongly associated with detectable PAH-DNA adduct levels compared with non-detectable adducts; additionally, no dose-response association was observed. Among a subgroup with treatment data (n=520), adducts were associated with over a two-fold higher mortality among those receiving radiation, but mortality for adducts was reduced among hormone therapy users. Results from this large population-based study do not provide strong support for an association between detectable PAH-DNA adducts and survival among women with breast cancer, except perhaps among those receiving radiation treatment.
登录
查看更多内容
影响因子：
5.6
作者：
Sagiv, Sharon K.;Gaudet, Mia M.;Gammon, Marilie D.
通讯作者：
Gammon, Marilie D.
影响因子：
4.7
作者：
SANTELLA, RM;GRINBERGFUNES, RA;PERERA, FP
通讯作者：
PERERA, FP
影响因子：
8.4
作者：
HOLMBERG, L;LUND, E;MEIRIK, O
通讯作者：
MEIRIK, O
影响因子：
10.3
作者：
Chu, KC;Tarone, RE;Edwards, BK
通讯作者：
Edwards, BK
影响因子：
6.2
作者：
Ford, MB;Sigurdson, AJ;Bondy, ML
通讯作者：
Bondy, ML